HU-SBPH@EC2705A

LEOCH INT'L

STARGLORY HLDGS

INTELLIMARK W27

BEST FOOD HLDG

GAOYU FINANCE

EXTREME VISION

TIAN TU CAPITAL

HSC RESOURCES

EPI (HOLDINGS)

LAP KEI ENGRG

01177

CMB International has lowered the target price for SBP GROUP from HKD 9.4 to HKD 8.7, reflecting a downward adjustment in expectations for non-BD revenue. The company is expected to achieve a revenue growth of 10.3% to RMB 31.83 billion in 2025, with innovative product revenue growing by 26.2%. Adjusted net profit attributable to the parent company is expected to increase by 31.4% to RMB 4.54 billion. Revenue and net profit are expected to continue to grow from 2026 to 2028, maintaining a "Buy" rating

AASTOCKS

SBP GROUP

CITIC International lowered the target price for China National Pharmaceutical Group to 8.7 yuan, accelerating global layout

589720

510660

516610

159859

159316

44080

560600

159837

516820

516930

159102

159929

159506

159992

Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure

Tip Ranks

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Dacheng CSI All Share Health Care Equipment and Services ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

SIHUAN PHARM PREF OFFER

Penghua SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure

159892

588130

科兴生物制药股份有限公司

UBS has lowered the target price for SINO BIOPHARM to 11 yuan, maintaining a "Buy" rating. The report pointed out that last year the company's revenue was 31.8 billion yuan, a year-on-year increase of 10.3%, which was below expectations; net profit was 2.3 billion yuan, a year-on-year increase of 22%, also below expectations. The gross profit margin rose to 82.1%. Management expects double-digit growth in both revenue and profit this year. Although the earnings per share forecast for this year has been raised by 9.4%, the earnings per share forecasts for 2027 and 2028 have been lowered due to lower expectations for generic drug revenue

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Lishengpharma

UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"

513120

ARKG

Chinese biotech firms achieved a record US$60 billion in cross-border outlicensing deals in Q1 2026, a 73% increase from the previous year. This surge reflects multinational pharmaceutical companies' interest in China's innovative drug candidates. Notable deals include Sino Biopharmaceutical's US$1.53 billion agreement with Sanofi and Antengene's US$1.18 billion pact with UCB. The Chinese pharmaceutical market is projected to grow significantly, driven by an aging population and technological advancements in biotech, with revenues expected to reach US$2.1 trillion by 2030.

SCMP

iShares Global Healthcare

VG Health

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

GX CN BIOTECH

Health Care Select Sector SPDR

GF CSI HK Innovative Drugs Industry ETF(QDII)

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

ANTENGENE-B

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Sanofi

Invesco Biotechnology & Genome ETF

Bosera Hang Seng Health Care ETF(QDII)

SPDR S&P Health

China biotech deals hit record as innovative drugs draw global interest

Sino Biopharmaceutical (OTCMKTS:SBMFF) experienced a significant increase in short interest in March, rising 35.7% to 98,069,575 shares as of March 13th. This represents 0.5% of the company's shares sold short, with a days-to-cover ratio of 212,271.8 days based on an average trading volume of 462 shares. The stock opened at $0.76, with a 52-week range of $0.45 to $1.24. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investment options.

Market Beat

Navidea Biopharm

Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$9.17, Keeps at Buy

marketscreener

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$9.17, Keeps at Buy

00700

03690

02616

03330

02319

02259

On March 27th, Hong Kong stocks closed with all three major indices rising collectively, with the Hang Seng Index up 0.38% and the National Enterprises Index up 0.76%, showing better performance. The market continued its rebound trend but remained under pressure from previous high resistance levels. In terms of sectors, internet giants showed weak performance, while individual stocks in the catering, gold, and pharmaceutical sectors were active, with Baset Pharmaceutical-B soaring over 20%. Weak macroeconomic data kept market sentiment cautious, and risk appetite was somewhat limited

Market Heartbeat

TENCENT

MEITUAN

CSTONE PHARMA-B

LINGBAO GOLD

MENGNIU DAIRY

ZIJIN GOLD INTL

Hong Kong stock market closing | Hang Seng Index rose 0.38% but failed to break the high, BYD surged 3.7%

The next blockbuster BD deal is on its way

- China Biologic Products (01177.HK) reported a 2025 total revenue of 31.83 billion CNY, a year-on-year increase of 10.3%, with adjusted net profit rising 31.4% to 4.54 billion CNY.  
- The company has undertaken significant acquisitions, including a $950 million purchase of Auron Biopharma and a $1.2 billion acquisition of Hegia, positioning itself uniquely in the domestic pharmaceutical market.  
- With a target of launching nearly 20 innovative products by 2028, including advancements in oncology and chronic disease treatment, China Biologic aims for substantial international revenue growth through a dual strategy of acquisitions and global business development.

Wallstreetcn

CH BIOTECH SER

Buying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM

513700

Nomura released a report stating that China National Pharmaceutical last year saw a revenue increase of 10% year-on-year to 31.8 billion RMB, lower than the market expectation of 33.1 billion; net profit fell by 33% to 2.3 billion RMB, far below the expected 4.9 billion. Management indicated that adjusted profit was 4.5 billion RMB, an increase of 31%. The main difference stems from a fair value change of assets amounting to 2.1 billion RMB. Looking ahead to 2026, Nomura expects innovative drug and collaboration revenue to drive sales growth, adjusting the 2026 revenue forecast upward by 1.9%, but lowering the 2027 forecast by 1.6%, with the target price reduced from 9.17 RMB to 8.67 RMB, maintaining a "Buy" rating

Penghua CSI HK Connect Health Care Composite ETF

Nomura: China National Pharmaceutical's net profit last year significantly missed expectations due to one-time factors

Sino Biopharma's Profit Slips in 2025; Dividend Declared

Sino Biopharma's Profit Slips in 2025; Dividend Declared

Sino Biopharma Upgraded to AA in MSCI ESG Ratings

Sino Biopharma Upgraded to AA in MSCI ESG Ratings

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

HENGRUI PHARMA

Hengrui Pharma

INNOVENT BIO

3SBIO

CSPC PHARMA

OSL GROUP

CPIC

SUNSHINE INS

SANDS CHINA LTD

Sands China

WYNN MACAU

CR HOLDINGS

CHINA LIFE

China Life

MELCO INT'L DEV

GUOTAI JUNAN I

AIA-R

AIA Group

SJM HOLDINGS

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

HU-SBPH@EC2705A(28052.HK)

HU-SBPH@EC2705A Stock Performance Chart

CITIC International lowered the target price for China National Pharmaceutical Group to 8.7 yuan, accelerating global layout

Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure

UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"

China biotech deals hit record as innovative drugs draw global interest

Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update